Review
Public, Environmental & Occupational Health
Nikki de Rouw, Berber Piet, Hieronymus J. Derijks, Michel M. van den Heuvel, Rob ter Heine
Summary: Pemetrexed is a key drug in lung cancer treatment, but some patients may experience toxicities. Pharmacokinetics can predict toxicity risk, and various strategies can help prevent and manage toxicities.
Article
Oncology
Nicholas J. J. Vogelzang, James J. J. Rusthoven, James Symanowski, Claude Denham, E. Kaukel, Pierre Ruffie, Ulrich Gatzemeier, Michael Boyer, Salih Emri, Christian Manegold, Clet Niyikiza, Paolo Paoletti
Summary: The purpose of this study was to evaluate the efficacy of pemetrexed plus cisplatin in the treatment of patients with malignant pleural mesothelioma. The results showed that compared to cisplatin alone, the combination of pemetrexed and cisplatin can prolong the overall survival time, progression-free survival time, and improve the response rates in patients with malignant pleural mesothelioma. Addition of folic acid and vitamin B-12 can significantly reduce the toxicity of the treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Chemistry, Medicinal
Krishna Kaku, Manasa P. Ravindra, Nian Tong, Shruti Choudhary, Xinxin Li, Jianming Yu, Mohammad Karim, Madelyn Brzezinski, Carrie O'Connor, Zhanjun Hou, Larry H. Matherly, Aleem Gangjee
Summary: This study found that adding a 6-methyl moiety to 5-substituted pyrrolo-[2,3-d]-pyrimidine antifolates can selectively inhibit the transport by RFC, achieving tumor-targeted therapy.
ACS MEDICINAL CHEMISTRY LETTERS
(2023)
Article
Oncology
Giorgio Vittorio Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, Ulrich Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Goksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David Gandara
Summary: This phase III randomized study compared the efficacy of cisplatin plus gemcitabine and cisplatin plus pemetrexed in the treatment of advanced non-small-cell lung cancer (NSCLC). The results showed that cisplatin plus pemetrexed was noninferior to cisplatin plus gemcitabine in terms of overall survival. However, cisplatin plus pemetrexed showed superior survival in patients with adenocarcinoma and large-cell carcinoma histology, while cisplatin plus gemcitabine was more effective in patients with squamous cell histology. Cisplatin plus pemetrexed also had less adverse reactions and more convenient administration.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Takashi Kasai, Kiyoshi Mori, Yoichi Nakamura, Nobuhiko Seki, Yasuko Ichikawa, Haruhiro Saito, Tetsuro Kondo, Kazuo Nishikawa, Satoshi Otsu, Akihiro Bessho, Hiroshi Tanaka, Hiroyuki Yamaguchi, Takayuki Kaburagi, Hisao Imai, Keita Mori, Junya Ohtake, Hiroaki Okamoto
Summary: The addition of bevacizumab to cisplatin and pemetrexed combination therapy as maintenance treatment prolongs progression-free survival in patients with untreated, advanced, non-squamous NSCLC. Early response to induction therapy and pretreatment monocytic myeloid-derived suppressor cell counts may be associated with the survival benefit of adding bevacizumab.
Article
Multidisciplinary Sciences
Santosh Kesari, Feng Wang, Tiffany Juarez, Shashaanka Ashili, C. Pawan K. Patro, Jose Carrillo, Minhdan Nguyen, Judy Truong, Joan Levy, Josh Sommer, Daniel M. Freed, Joanne Xiu, Yuki Takasumi, Eric Bouffet, Jaya M. Gill
Summary: Chordomas are rare tumors that have a high tendency to recur and currently lack effective treatment options. A study found that the drug Pemetrexed, which inhibits enzymes involved in folate metabolism, showed activity against chordomas in preclinical models. Three cases of metastatic chordoma that had poor response to standard therapies showed objective responses when treated with Pemetrexed.
SCIENTIFIC REPORTS
(2023)
Article
Chemistry, Organic
Rama Mohana Reddy Jaggavarapu, Venkatanarayana Muvvala, Venkatareddy Ghojala, H. Sharath Babu, Ravi Kumar Cheedarala
Summary: A facile synthetic protocol was used to prepare process-related impurities associated with the synthesis of pemetrexed disodium heptahydrate, Alimta. The study describes the development of novel synthetic methods and their structure elucidation for Pemetrexed glutamide, N-methyl pemetrexed, and N-methyl pemetrexed glutamide impurities. These impurities were deduced through spectral analysis and can serve as reference substances for quality control.
CURRENT ORGANIC SYNTHESIS
(2022)
Article
Biochemistry & Molecular Biology
Adrianne Wallace-Povirk, Nian Tong, Jennifer Wong-Roushar, Carrie O'Connor, Xilin Zhou, Zhanjun Hou, Xun Bao, Gloria E. Garcia, Jing Li, Seongho Kim, Charles E. Dann, Larry H. Matherly, Aleem Gangjee
Summary: The study identified first-in-class C1 inhibitors with selective uptake by FRs and dual inhibition of enzyme targets in de novo purine biosynthesis, resulting in anti-tumor activity. This series offers an exciting new platform for selective multi-targeted anti-tumor agents.
BIOORGANIC & MEDICINAL CHEMISTRY
(2021)
Article
Immunology
Oriana Kreutzfeld, Patrick K. Tumwebaze, Oswald Byaruhanga, Thomas Katairo, Martin Okitwi, Stephen Orena, Stephanie A. Rasmussen, Jennifer Legac, Melissa D. Conrad, Sam L. Nsobya, Ozkan Aydemir, Jeffrey A. Bailey, Maelle Duffey, Roland A. Cooper, Philip J. Rosenthal
Summary: This study investigated the susceptibility of P falciparum field isolates to PfDHFR inhibitors in two districts of Uganda and found common resistance-mediating mutations in Uganda. However, the new compound P218 retained excellent activity against mutant parasites.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Oncology
Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto
Summary: The JME-001 trial aimed to evaluate the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma. Preliminary results showed a high objective response rate and disease control rate in the majority of patients, but also a significant rate of adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Pharmacology & Pharmacy
Nikki de Rouw, Merel de Boer, Rene J. Boosman, Michel M. van den Heuvel, David M. Burger, Joris E. Lieverse, Hieronymus J. Derijks, Geert W. J. Frederix, Rob ter Heine
Summary: This study investigates the costs and benefits of individualized dosing of pemetrexed in reducing the incidence of neutropenia. The results show that individualized dosing can lead to significant cost savings and decreased risk of neutropenia-related hospitalization or death.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Pharmacology & Pharmacy
Jiahong Xiang, Mengqi Wu, Jianchao Wang, Mengmeng Lin, Mengmeng Sun, Xin Li, Ruijuan Xing, Ran Guo, Jianmin Gu, Tao Lyu, Lei Wang, Xiaowei Shi
Summary: Glytrexate, a novel multitarget folate antagonist developed by our team, shows inhibitory effects on various cancer cell types, especially KB tumor cells. A liquid chromatography-tandem mass spectrometry method was developed and applied to evaluate the stability, plasma protein binding, and pharmacokinetics of glytrexate. Results suggest that glytrexate has potential clinical application prospects as an injection formulation compared to oral administration.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Chao Tian, Yifei Chen, Meng Wang, Jing Cong, Hao Li, Suwei Dong, Xiaowei Wang, Junyi Liu, Zhili Zhang
Summary: A series of 2,6-diamine-9H-purine derivatives substituted with phenyl groups at the 8-position through three carbon bridges were synthesized and tested for their anti-proliferative activities against HL60, HeLa, and A549 cells. Compound 4e showed the best inhibitory activity against HL-60 and HeLa cells. Flow cytometry studies revealed that 4e induced S-phase arrest and apoptosis in HL-60 cells, acting through a lysosome-nonmitochondrial pathway. These findings suggest that compound 4e has potential as a novel potent anticancer agent.
MEDICINAL CHEMISTRY RESEARCH
(2023)
Article
Oncology
Nasser Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller, Hong-Liang Lim, Christopher Desch, Klara Szondy, Radj Gervais, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn
Summary: The study aimed to compare the efficacy and toxicity of pemetrexed and docetaxel in patients with advanced non-small-cell lung cancer previously treated with chemotherapy. The results showed that both pemetrexed and docetaxel had low overall response rates and there was no significant difference in progression-free survival and overall survival between the two drugs. However, pemetrexed had significantly fewer side effects compared to docetaxel and should be considered as a standard treatment option for second-line non-small-cell lung cancer when available.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Rayees Ahmad Naikoo, Rupesh Kumar, Rashmi Sharma, Dinesh Mahajan, Gaurav Bhargava
Summary: The manuscript describes a highly regioselective 6-exo-dig iodo/bromo cyclization of functionalized N-propagyl-amino-pyrimidinones under ambient conditions, resulting in the synthesis of functionalized pteridines with excellent yields. The optimized procedures are mild, operationally simple, and effective with different substrates. The synthesis of functionalized pteridines is of great significance due to their potential pharmacological profile.
Article
Biochemistry & Molecular Biology
Ryan M. Carr, Paola A. Romecin Duran, Ezequiel J. Tolosa, Chenchao Ma, Abdul M. Oseini, Catherine D. Moser, Bubu A. Banini, Jianbo Huang, Faizal Asumda, Renumathy Dhanasekaran, Rondell P. Graham, Merih D. Toruner, Stephanie L. Safgren, Luciana L. Almada, Shaoqing Wang, Mrinal M. Patnaik, Lewis R. Roberts, Martin E. Fernandez-Zapico
JOURNAL OF BIOLOGICAL CHEMISTRY
(2020)
Article
Biochemistry & Molecular Biology
Stephanie L. Safgren, Rachel L. O. Olson, Anne M. Vrabel, Luciana L. Almada, David L. Marks, Nelmary Hernandez-Alvarado, Alexandre Gaspar-Maia, Martin E. Fernandez-Zapico
JOURNAL OF BIOLOGICAL CHEMISTRY
(2020)
Article
Multidisciplinary Sciences
Ryan M. Carr, Denis Vorobyev, Terra Lasho, David L. Marks, Ezequiel J. Tolosa, Alexis Vedder, Luciana L. Almada, Andrey Yurcheko, Ismael Padioleau, Bonnie Alver, Giacomo Coltro, Moritz Binder, Stephanie L. Safgren, Isaac Horn, Xiaona You, Eric Solary, Maria E. Balasis, Kurt Berger, James Hiebert, Thomas Witzig, Ajinkya Buradkar, Temeida Graf, Peter Valent, Abhishek A. Mangaonkar, Keith D. Robertson, Matthew T. Howard, Scott H. Kaufmann, Christopher Pin, Martin E. Fernandez-Zapico, Klaus Geissler, Nathalie Droin, Eric Padron, Jing Zhang, Sergey Nikolaev, Mrinal M. Patnaik
Summary: The research focuses on the relationship between proliferative chronic myelomonocytic leukemia (pCMML) and RAS pathway mutations, revealing that RAS mutations lead to a unique gene expression profile enriched in mitotic kinases such as PLK1. The study suggests that inhibiting RAS-driven PLK1 expression could be a viable therapeutic target for pCMML.
NATURE COMMUNICATIONS
(2021)
Review
Oncology
Jonathan Gill, Richard Gorlick
Summary: Osteosarcoma, the most common primary bone cancer in children and young adults, presents challenges in treatment due to its rarity and molecular heterogeneity. Collaborative efforts in biological discoveries, technologies, and therapeutic approaches are expected to advance osteosarcoma treatment and improve patient outcomes. The increasing feasibility of molecular profiling, along with the creation of robust model systems and large tissue banks, has enhanced understanding of osteosarcoma biology.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Oncology
Anderson B. Collier, Mark D. Krailo, Ha M. Dang, Steven G. DuBois, Douglas S. Hawkins, Mark L. Bernstein, Lisa R. Bomgaars, Damon R. Reed, Richard G. Gorlick, Katherine A. Janeway
Summary: Analysis of seven Children's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors showed a 6-month event-free survival (EFS) of 12.7% for relapsed/progressive Ewing sarcoma patients, indicating poor outcomes. Despite docetaxel achieving its protocol-specified radiographic response rate, its EFS was similar to other agents, suggesting that a higher radiographic response rate may not lead to superior disease control. This EFS benchmark could be used as an additional endpoint in trials for recurrent Ewing sarcoma.
PEDIATRIC BLOOD & CANCER
(2021)
Article
Cell Biology
Xin Zhou, Allyson Beilter, Zhaohui Xu, Ruli Gao, Shunbin Xiong, Adriana Paulucci-Holthauzen, Guillermina Lozano, Benoit de Crombrugghe, Richard Gorlick
Summary: This study identified chondrocytes as an additional source for mesenchymal progenitor cells (MPCs) and showed that Wnt/ss-catenin pathway discretely regulates the development from chondrocytes to C-MPC and subsequently from C-MPC to osteoblasts. Furthermore, the study unveiled a previously unrecognized functional link between ss-catenin and p53, with p53 playing a negative role in MPC osteogenic differentiation induced by Wnt/ss-catenin signaling.
CELL DEATH & DISEASE
(2021)
Article
Genetics & Heredity
Stephanie L. Safgren, Rory J. Olson, Filippo Pinto e Vairo, Erick D. Bothun, Christian Hanna, Eric W. Klee, Lisa A. Schimmenti
Summary: This case presents a patient with multiple systemic defects, with a loss of function variant identified in association with PBX1 through genetic testing. Research suggests that PBX1 is related to eye development, possibly explaining the patient's presentation of glaucoma.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A
(2022)
Article
Oncology
Qing Yang, Jiemiao Hu, Zhiliang Jia, Qi Wang, Jing Wang, Long Hoang Dao, Wendong Zhang, Sheng Zhang, Xueqing Xia, Richard Gorlick, Shulin Li
Summary: This study proposes a new cell therapy for treating osteosarcoma. By introducing a specific protein into peripheral blood mononuclear cells, tumor growth can be effectively inhibited without observable toxicity.
CLINICAL CANCER RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Emily J. Koubek, Sarah A. Buhrow, Stephanie L. Safgren, Lee Jia, Matthew P. Goetz, Matthew M. Ames, Joel M. Reid
Summary: This study investigated the pharmacokinetics and oral bioavailability of ENDX in rats and dogs. The results indicated that ENDX has high oral bioavailability and leads to higher plasma concentrations compared to equivalent doses of TAM. These findings support the development of ENDX as a drug for the treatment of estrogen receptor-positive breast cancer.
DRUG METABOLISM AND DISPOSITION
(2023)
Correction
Medicine, General & Internal
Hannah C. Beird, Stefan S. Bielack, Adrienne M. Flanagan, Jonathan Gill, Dominique Heymann, Katherine A. Janeway, J. Andrew Livingston, Ryan D. Roberts, Sandra J. Strauss, Richard Gorlick
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Medicine, General & Internal
Hannah C. Beird, Stefan S. Bielack, Adrianne M. Flanagan, Jonathan Gill, Dominique Heymann, Katherine A. Janeway, J. Andrew Livingston, Ryan D. Roberts, Sandra J. Strauss, Richard Gorlick
Summary: Osteosarcoma is the most common primary malignant bone tumor with a bimodal incidence peaking at 18 and 60 years of age. It is more common in males and is driven by genetic factors related to bone formation leading to malignant progression and metastasis. Screening is currently focused on high-risk groups, and the prognosis for patients with metastatic disease remains poor.
NATURE REVIEWS DISEASE PRIMERS
(2022)
Article
Multidisciplinary Sciences
Qi Jin, Blanca Gutierrez Diaz, Tim Pieters, Yalu Zhou, Sonali Narang, Igor Fijalkwoski, Cristina Borin, Jolien Van Laere, Monique Payton, Byoung-Kyu Cho, Cuijuan Han, Limin Sun, Valentina Serafin, George Yacu, Wouter Von Loocke, Giuseppe Basso, Giulia Veltri, Ingrid Dreveny, Issam Ben-Sahra, Young Ah Goo, Stephanie L. Safgren, Yi-Chien Tsai, Beat Bornhauser, Praveen Kumar Suraneni, Alexandre Gaspar-Maia, Irawati Kandela, Pieter Van Vlierberghe, John D. Crispino, Aristotelis Tsirigos, Panagiotis Ntziachristos
Summary: This study reveals that in T cell acute lymphoblastic leukemia (T-ALL), ubiquitin-specific protease 11 (USP11) forms a complex with USP7 to deubiquitinate the oncogenic lymphocyte cell-specific protein-tyrosine kinase (LCK) and enhance its activity. Impairment of LCK activity leads to increased glucocorticoid receptor (GR) expression and glucocorticoids sensitivity. Additionally, the deubiquitinase activity plays a role in the transcriptional activation of GR target genes.
Article
Biochemistry & Molecular Biology
Jiayi Sun, Wing-Yuk Chow, Gufeng Xu, M. John Hicks, Manjula Nakka, Jianhe Shen, Patrick Kwok Shing M. Ng, Aaron Taylor, Alexander E. Yu, Jason A. Farrar, Donald Barkauskas, Richard M. Gorlick, Jaime M. Guidry Auvil, Daniela Gerhard, Paul Meltzer, Rudy Guerra, Tsz-Kwong C. Man, Ching Lau, TARGET Osteosarcoma Consortium
Summary: Osteosarcoma is a primary malignant bone tumor that commonly metastasizes to the lungs. Altered FAS expression due to DNA methylation has been explored as a mechanism in cancer cells. Analysis revealed high variability in methylation of CpG sites that correlated with FAS mRNA expression. Treatment with demethylating agent 5-azacytidine restored FAS protein expression and reduced metastasis in osteosarcoma cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biotechnology & Applied Microbiology
Celestia Fang, Zhenjia Wang, Cuijuan Han, Stephanie L. Safgren, Kathryn A. Helmin, Emmalee R. Adelman, Valentina Serafin, Giuseppe Basso, Kyle P. Eagen, Alexandre Gaspar-Maia, Maria E. Figueroa, Benjamin D. Singer, Aakrosh Ratan, Panagiotis Ntziachristos, Chongzhi Zang
Article
Oncology
Swaathi Jayaraman, Xiaonan Hou, Mary J. Kuffel, Vera J. Suman, Tanya L. Hoskin, Kathryn E. Reinicke, David G. Monroe, Krishna R. Kalari, Xiaojia Tang, Megan A. Zeldenrust, Jingfei Cheng, Elizabeth S. Bruinsma, Sarah A. Buhrow, Renee M. McGovern, Stephanie L. Safgren, Chad A. Walden, Jodi M. Carter, Joel M. Reid, James N. Ingle, Matthew M. Ames, John R. Hawse, Matthew P. Goetz
BREAST CANCER RESEARCH
(2020)